Angiotensin Receptors (Angiotensin II Receptor)

02/24/2004 - "Although angiotensin II receptor blockade is considered to be useful for the treatment of human heart failure, little beneficial hemodynamic effect has been shown in some experimental failing hearts. "
09/01/2010 - "These results imply that the angiotensin II receptor (type 1) contributes to heart failure due to CSQ overexpression, as its blockade improved survival."
05/01/2001 - "New agents that target selective blockade of the angiotensin II receptor have been introduced in clinical trials for the treatment of heart failure. "
06/01/1999 - "This study should help establish the role of angiotensin-receptor blockade in the treatment of heart failure."
01/01/2021 - "[A novel way of modification of AT1 angiotensin receptors to alleviate neonatal and infantile heart failure]."

05/19/2022 - "Pharmacological (angiotensin II receptor type 1 receptor blocker use) and non-pharmacological treatment (physical aerobic exercise) are important strategies to reduces blood pressure and control arterial hypertension; however, only few clinical studies have evaluated their combined effects on autonomic cardiovascular control. "
10/01/2008 - "The Trial of Preventing Hypertension demonstrated that angiotensin receptor blockade safely lowers blood pressure and prevents or delays progression to hypertension in stage 2 prehypertensives. "
08/01/2008 - "The Trial of Preventing Hypertension (TROPHY) documented that angiotensin receptor blockade safely lowers BP and prevents and/or delays hypertension in Stage 2 prehypertensives. "
08/01/2007 - "The Trial of Prevention of Hypertension demonstrated that angiotensin receptor blockade (ARB) retards age-related BP increases in prehypertensive patients. "
01/01/1999 - "Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. "

08/01/2005 - "[Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy]."
06/01/2010 - "Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus."
12/01/2006 - "Angiotensin II receptor Type 1 antagonists postpone the development of nephropathy in type 2 diabetes mellitus (DM). "
01/01/2006 - "However, the effect of angiotensin II receptor blockade on monocyte and endothelial cell adhesion markers in type 2 diabetes is poorly understood. "
04/01/2005 - "Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes."

01/01/2018 - "rs146662057 is located within an active enhancer associated with the expression of Angiotensin II Receptor type 2 gene (AGTR2), a modulator of insulin sensitivity, and exhibits allelic specific activity in muscle cells. "
10/01/2001 - "Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats."
10/01/2008 - "This study seeks to determine the effect of angiotensin receptor blockade (ARB) on insulin resistance of adipocytes in culture and in a rat model of type 2 diabetes. "
07/01/2013 - "Angiotensin receptor (type 1) blockers (ARBs) can reduce both hypertension and insulin resistance induced by local and systemic activation of the renin-angiotensin-aldosterone system. "
02/01/2013 - "Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure."

01/01/2023 - "We aim to test the hypothesis that compared with angiotensin II receptor blockade (ARB) alone, ARNi is more effective in regressing diffuse interstitial myocardial fibrosis in HHD. "
08/01/2007 - "In this study, we assessed the hypothesis that the expression of angiotensin II receptor type 1 (AGTR1) in liver tissue changes with increasing fibrosis, which would influence the antifibrotic efficacy of AGTR1 blockers. "
10/01/2020 - "Future studies should focus on the role of angiotensin receptor inhibitors in preventing myocardial fibrosis in patients with LVADs and examine in greater details the target blood pressure for these patients."
01/18/2019 - "Our study identified that HKMT-induced pleural fibrosis is mediated by NOX4⁻ERK⁻ROS via TLR4 and Angiotensin II receptor type1 (AT1R). "
01/01/2020 - "Fibrosis of the aortic wall and expression of angiotensin receptors increased in TAC rats, which was attenuated by MGCD. "